Deeplife

{"summary_one_liner":"Paris-based AI techbio building digital twins of cells to identify drug targets and reposition drugs.","detailed_description":"DeepLife is a French biotech/\"AI techbio\" company that builds digital twins of cells to model cellular behaviour and disease mechanisms. Its platform combines multi-omics sequencing data, public and private single-cell atlases, causal AI and systems engineering to simulate disease at the single-cell level and identify molecular triggers that can shift diseased cells back toward a healthy state. The company positions this as a way to compress target discovery from years to months and to raise reliability versus what it describes as the industry's 0.01% success rate (sources [2], [5], [6]).\n\nThe company describes two main offerings on its site: a Cell Blueprint platform (also referenced as TwinCell, with an API) for decoding cellular mechanisms, and an AI-driven drug repositioning pipeline. Earlier company descriptions characterise the product as a SaaS platform for digital twins of cells, intended to supplement in vitro testing with in silico simulation and to serve biotech and pharmaceutical partners in target identification ([0], [2], [3], [5]).\n\nDeepLife's disclosed pipeline covers autoimmune, skin and neurodegenerative indications, including inflammatory bowel disease (assets DL-IBD-001 and DL-IBD-002), atopic dermatitis, acne, psoriasis, Alzheimer's, Parkinson's, multiple sclerosis and glioblastoma. Programs shown are at in silico discovery and preclinical (in vitro / in vivo) stages, with no assets listed in IND-enabling or clinical phases ([3])."},"business_model":"DeepLife works with biotech and pharmaceutical companies to accelerate target identification, historically framed as a SaaS platform for digital twins of cells; it also collaborates with the academic community by publishing papers and providing open access to certain platform features and data. In addition, it develops its own drug repositioning pipeline and offers out-licensing and co-development opportunities in autoimmune and neurodegenerative disease ([3], [5]).","company_history":"Founded in 2019 in Paris by Jonathan Baptista and Jean-Baptiste Morlot. Investor data lists a funding round of about $6M dated October 2022 and a Series A of $10M announced in December 2024, with YZR Capital joining at the Series A stage in 2024; a December 2024 Sifted article reported the $10M raise and that the company was considering relocating to the US ([2], [4], [5], [6]).","differentiation":"The company presents itself as having developed the first SaaS platform for digital twins of individual cells, combining multi-omics data, causal AI and systems engineering to model cell-type-specific interactomes and identify driver genes, with claimed reductions in target discovery time from years to months. Its repositioning approach uses FDA-approved or safety-validated drugs, which it says allows Phase 1 to be skipped, saving over 10% of cost per asset and shortening timelines by up to 40% ([2], [3], [5], [6]).","founding_story":"Jonathan Baptista (CEO) and Jean-Baptiste Morlot (CTO) founded DeepLife in 2019 to address inefficiencies in drug development. According to the company, the concept combined Baptista's background in engineering simulation tools with Morlot's AI genetics research to create digital twins of cells that simulate cellular behaviour and predict drug responses ([2], [6]).","geographic_footprint":"Headquartered in Paris, Île-de-France, France; one investor database instead lists Vernon, France. YZR Capital describes the company as Paris-based. A December 2024 report noted the company was weighing a US relocation ([4], [5], [6]).","go_to_market":"Direct engagement with biotech and pharmaceutical partners for target identification and scientific collaboration (the website routes inbound contacts to business, scientific collaboration, recruitment, investor and media teams), plus partnering, out-licensing and co-development of internal pipeline assets ([0], [3], [5]).","latest_developments":"In December 2024 DeepLife raised a $10M Series A; coverage at the time indicated the company was considering a move to the United States. Investor pages list its current stage as Series A ([4], [6]).","market_position":"Positioned as an AI techbio in computational drug discovery, categorised under artificial intelligence, biotechnology and machine learning, and backed by investors including Bpifrance, Entrepreneurs First, Kima Ventures, Creative Destruction Lab, YZR Capital and Turenne Groupe ([4], [6]).","revenue_model":"Sources describe a SaaS platform offering for pharma and biotech partners and, separately, out-licensing and co-development opportunities on internal pipeline assets; no pricing or contract terms are disclosed ([3], [5]).","risks_controversies":"Sources disclose no controversies. Data inconsistencies exist across third-party aggregators: headquarters is listed as both Paris and Vernon, France, and total funding is reported as $10.0M by one database and $16M (two rounds) by another, with the Series A dated December 2024 in one source and January 2025 in another ([4], [5], [6]).","target_customers":"Biotech and pharmaceutical companies seeking accelerated target identification and drug development partners, plus academic research collaborators ([3], [5]).","technology":"Deep learning applied to multi-omics sequencing data, public and private cell atlases, causal AI and network medicine approaches, and proprietary cell engineering tools, delivered through a platform (Cell Blueprint / TwinCell) with an API. Workflow stages described include building disease single-cell atlases, cell-type-specific differential expression and causal analysis on interactomes to identify driver genes, target scorecards ranked on druggability, safety and novelty, and drug repositioning against a curated drug catalog ([0], [3], [5]).","traction":"The company reports a team of 25 employees across 15 nationalities, about 90% holding PhDs in fields such as computational biology, genetics and machine learning. A third-party profile lists 21-50 employees. The pipeline shows two named IBD assets at in vitro and in silico repurposing stages, with additional programs in dermatology and neurodegeneration; no assets are in IND-enabling or clinical phases ([2], [3], [5])."}